Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Indeed. Recycled. Lack of updates have shareholders clinging.
Youtube indicates that this video was posted 2 weeks ago but I was a little confused by some of the comments versus the timing of the interview.
- Early on in the video Ron mentioned Phil Boshua's role in the early development and told the moderator he should speak with him... I had the impression that there was some animosity between Phil and Know Labs after his departure.
- Later in the video Ron mentioned that they wanted to uplist to NASDAQ... if they are already listed on NYSE why would they be talking about a NASDAQ listing?
- Also, Ron mentioned that Dexcom has a $60B market cap... 2 weeks ago Dexcom's market cap was about $30B and the $60B market cap was from 6 months ago.
Know Labs - Revolutionizing Non-Invasive Medical Diagnostics
It's certainly been a slow journey but many of the current longs have accumulated when the stock was low-priced. My cost basis is below 50 cents so I'm not too worried. I expect this will be a classic example of Buffett's maxim that "The stock market is designed to transfer money from the active to the patient".
Thomas Edison has been exposed for orchestrating one of the most audacious cons in industrial history, crafting hundreds of failed lightbulbs to fleece investors out of millions while feigning imminent breakthroughs. The so-called "Wizard of Menlo Park" employed a legion of "scientific consultants" to inflate his failure count, ensuring that his investors remained perpetually on the hook while his own fortune flourished. And then, in a final evil twist, he succeeded in creating the first working lightbulb-- thereby defrauding the honorable shorts and rewarding the scoundrels who supported him all along.
Longs have officially been fucked over by Ron. Thanks all 😊
Hate to say "I told y'all so." You're welcome.
So they demolish the stock price to get the new international investors on board???Just goes to show that little guys don't stand much of a chance as companies like this dilute at will and rs as part of their growth strategy. They couldn't raise money at .50,.60.70 cents verses who knows how low the offering will ultimately be?
They only tapped into $4M of the lind deal. Don’t listen to that Ham guy, he has no idea what he’s talking about.
My guess is new offering is being bought up by foreign investors since they brought on the new international president.
There is a s-1 that has been filed. Blank as to $ amount from what i can tell. It showed as Restricted stock until the company clears fda. But no matter is still very confusing, why do such when you just did a 12$ mil deal with Lind Partners? Maybe Phil back to angry and dumping his stash again.
Is this price collapse just short sellers bringing it down from $.82 to sub $.40 now or is there some fundamental news behind this drop?
Between 2005 and 2018, the FDA cleared several CGM devices with a wide range of MARDs: 17.2%, 13.6%, 18.3%, and 8.7%-9.14%.
https://link.springer.com/article/10.1007/s41745-022-00348-3
The decision to clear a medical device depends on a variety of factors including safety, efficacy, and overall benefit-risk profile. If a new CGM demonstrates substantial advantages despite a slightly higher MARD, it could still be favorably reviewed.
In my opinion, the non-invasiveness, lack of consumables, and overall lower cost of the KNOW Labs device, along with consistent MARDs in the 11-12% range, makes it highly likely to receive FDA clearance in the near future.
Saw an interesting journal article comparing the MARD between the Dexcom G7 and the the Abbott FreeStyle 3. In past discussions on this board, there has been concern that the MARD of the KnowU device was only around 11.1% while Dexcom claimed a MARD of 8.2% for the G7.
The journal paper from the beginning of this year, Comparison of Point Accuracy Between Two Widely Used Continuous Glucose Monitoring Systems, described testing that showed the true MARD of the G7 to be 13.6%. The journal article also noted that the MARD was over 27% in low glucose ranges (mg/dL<70). The paper found the FreeStyle device was fairly accurate with a MARD of 8.9% and consistent accuracy over all glucose ranges.
This should be encouraging news for folks who've invested in KNW and are concerned about potential FDA approval.
Leo Trautwein Presents Know Labs at LSI USA '24
Great video. He goes into much more detail about the design and testing process. I believe they're on track to make significant progress.
No. I am not. Sorry. Just saw this now.
Are Non-Invasive CGMs the Future? Best Interview Steve Kent
“Kent said in the video that Know Labs is planning to further pare down the wearable device housing the sensor, though the company noted in Tuesday’s announcement that the sensor itself is the same one it will eventually be submitting to the FDA.”
https://www.fiercebiotech.com/medtech/know-labs-finalizes-noninvasive-glucose-sensor-design-sets-sights-fda-pivotal-trial
KNW will never make those marks. You should have shorted when the volume enabled.
Thanks so much for the Adult explanation. It's good to know we have smart and intelligent people following KNW. It is good to know that KNW is in the area and there are people rooting for this tech to succeed. This sounds exciting and looking forward to a better future for diabetics.
So, Squide your telling me that it's great that Know labs will fail and poor Diabetics will have to continue to pay 5 to $700. per month for a sensor that monitors their blood sugar. You must work for Dexcom or your a pretty poor Human Being.
They need a MARD of below 10% and they’ve gotten it down to ~11%. They’re now about one percent away from creating the first non-invasive CGM— which would instantly leapfrog the competition.
CGMs are a 4.6 billion dollar market that’s estimated to reach 18 billion by 2028.
As long as they keep making measurable progress I will happily wait. :)
Either you or Ron will die before these guys are able to bring on revenue. Sorry
OK guys and gals. We faithfull for many years are finally seeing hard numbers come out on the efficacy of that wonderfull piece of technology that has been invented and we see the first generation of the product with our very own eyes. The question on my mind is is it good enough to be competitive. I checked on the MARD #s of the G7 and it seems to be able to give a MARD # of 8.5 and our Uband comes in at 11.1. Does anyone out there have a clue as to what would be a good enough MARD for the FDA? It does seem that minuturizing the lab unit to the Uband unit has increased the MARD from 6.5 to 11.1 and I know the lab test is not real world but can that be improved on? I sure hope somebody in the know can answer this. Sure hoping this comes to market soon. I ain't gettin any youger. Been here for 14 years now and still waiting and hoping.
This stock plunges more often than a Pelican behind a school of fish. I guess investors are tired of waiting for the oft-promised but not-yet-delivered CGM device.
Funding from Lind. Oh boy, who's seen their track record?!
KNW......................................https://stockcharts.com/h-sc/ui?s=KNW&p=W&b=5&g=0&id=p86431144783
With todays news, I can't believe anyone is selling!
What Happened today. WOW. Somebody has to know something. Up 40% in one day. That's amazing, and yet no comments. Where is everybody/
"John Cronin was added to the Know Labs Board in November 2023 to play a pivotal role in its growth.
He is a Rock Star.
Why would someone like this join Know Labs?
“John Cronin is the founder and CEO of ipCapital Group, Inc., a leading global advisory company on intellectual property strategy and monetization. Cronin began his career at IBM where he was the sole inventor of breakthrough chip design technology that became the company’s most valuable patent, generating $500 million in revenue.
He went on to create the IBM Patent Factory and grew IBM’s patent portfolio from ninth to number one in the world. He played a pivotal role in increasing IBM’s patent licensing revenue from $30 million to over $2 billion a year. Cronin has been a strategic advisor and consultant to Know Labs, supporting the company’s expanding patent portfolio from 86 to 246 patents issued, pending and in process over the last twelve months, increasing its global leadership in the non-invasive blood glucose monitoring category.”
Biography
John Cronin is Chairman and CEO of ipCapital Group, Inc. (“ipCG”), an intellectual property consulting firm. Mr. Cronin founded ipCG in 1998.
Mr. Cronin and ipCG have worked with over 1,200 companies and approximately 10% of the Fortune 500 companies, hundreds of mid-size companies, and hundreds of startups and governmental laboratories. Over the years, Mr. Cronin has become a respected thought leader among executives who wish to align business issues with IP and translate strategies into actionable financial results. Mr. Cronin has inspired and trained thousands of engineers and scientists in the best practices of “how to invent.”
Mr. Cronin has authored greater than 1500 patents and applications across hundreds of technology spaces, leveraging the ipCapital Methodology."
Yeah. What was that?! Does someone know something? I wonder if something leaked.
I'm so glad Know Labs empathizing the children. My boy was 2 1/2 when he came down with type 1.
During the conference Know Labs will sponsor an invitation-only luncheon hosted by Children With Diabetes (CWD) where key thought leaders in the diabetes management field will discuss non-invasive glucose monitoring innovation.
How AI and ML Are Scaling Data Collection to Transform Medical Monitoring
Steve Kent, is the Chief Product Officer at Know Labs.
https://www.unite.ai/how-ai-and-ml-are-scaling-data-collection-to-transform-medical-monitoring/
Oh, I check in now and then. I sold enough stock for a 200% profit, but I’m hanging on to all the rest— which is plenty.
That MARD is getting close. Best bet, in my opinion, is to measure against blood glucose readings instead of Dexcom, which isn’t perfect, but that will mean a longer approval process.
It will be worth it in the end. :)
Aren't you in Rockley too?
Because the largest KNW shareholder purchased 14 million shares of the private placement. See Form 13D
Why do I get the feeling that the 25cent shares are long gone?
I had signed up for it but am unable to attend. This is the closest conference to me so far. It is in the Bay Area. I live in Socal. Still about 400 Miles away. I was definitely going to track them down. Can't go unfortunately. This is not the timeline that I imagined back in 2018 when Phil announced the tech. The worst part is the dilution. I will be pissed beyond reason if they RS us again. My patience is finally wavering.
Just about 25 years of R&D, close to $130m to monetize what?
Investors getting slaughtered
Last year this stock traded close to $3 premarket during the last offering, now 25 cents
CEO should at least send out condolence cards to his loyal shareholders
You're at Imagine, correct? I'd track these clowns down and ask why they are so piss poor at managing a project and ask for a reasonable timeline. Ask Ron how end of 2023 turned to 2025-2026. I'd also ask why insiders aren't buying at current prices if this is "the holy grail of the medical industry."
I think the market will have many opportunities to buy at current price or lower as they continue to dilute until 2026.
This is actually crazy. "Preparation" for De novo. 2026???????????????
As you know, I am a 12 year shareholder. Are we seeing the most elaborate shell game ever perpetrated? Keep leading us on??
Yes. Just keep adding shares to stay on the NYSE! Tell your investors where to stick it. True Ron fashion.
Where is Mantix hiding? I miss Mantix.
.25c —> 28MM shares. Fully diluted will be around 150MM.
WOW what a beat down. Still no official pricing that I can find
Where are they pricing this thing?
Rough market for another deal, supposed to price tonight for tomorrow last I heard
How about a weekly update on progress toward commercialization?
Followers
|
75
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3547
|
Created
|
10/19/08
|
Type
|
Free
|
Moderators |
About Know Labs, Inc.
Know Labs, Inc. (f/k/a Know Labs Incorporated) is a public company whose shares trade under the stock symbol “KNWN.” The company’s technology directs structured light or radio waves through a substance or material to capture a unique molecular signature. The Company refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye. ChromaID and Bio-RFID scanner modules can be integrated into a variety of mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests. For more information on Know Labs, visit the company’s website at http://bit.ly/knowlabs
Overview
Historically, the Company focused on the development of our proprietary ChromaID technology. Using light from low-cost LEDs (light emitting diodes) we map the color of substances, fluids and materials and with our proprietary processes we can authenticate, identify and diagnose based upon the color that is present. The color is both visible to us as humans but also outside of the humanly visible color spectrum in the near infra-red and near ultra-violet and beyond. Our ChromaID scanner sees what we like to call “Nature’s Color Fingerprint.” Everything in nature has a unique color identifier and with ChromaID we can see it, and identify, authenticate and diagnose based upon the color that is present. Our ChromaID scanner is capable of uniquely identifying and authenticating almost any substance or liquid using light to create, record and detect its unique color signature. We will continue to develop and enhance our ChromaID technology and extend its capacity. More recently, we have focused upon extensions and new inventions that are derived from and extend beyond our ChromaID technology. We call this technology Bio-RFID. The rapid advances made with our Bio-RFID technology in our laboratory have caused us to move quickly in to the commercialization phase of our Company as we work to create revenue generating products for the marketplace.
ChromaID and Bio-RFID: Foundational Platform Technologies
Our ChromaID and Bio-RFID technologies provide a platform upon which a myriad of applications can be developed. As platform technologies, they are analogous to a smartphone, upon which an enormous number of previously unforeseen applications have been developed. ChromaID and Bio-RFID technologies are “enabling” technologies that bring the science of electromagnetic energy to low-cost, real-world commercialization opportunities across multiple industries. The technologies are foundational and, as such, the basis upon which the Company believes a significant business can be built.
As with other foundational technologies, a single application may reach across multiple industries. The ChromaID technology can, for example effectively differentiate and identify different brands of clear vodkas that appear identical to the human eye. By extension, this same technology can identify pure water from water with contaminants present. It can provide real time detection of liquid medicines such as morphine that have been adulterated or compromised. It can detect if jet fuel has water contamination present. It could determine when it is time to change oil in a deep fat fryer. These are but a few of the potential applications of the ChromaID technology based upon extensions of its ability to identify different clear liquids.
Similarly, the Bio-RFID technology can non-invasively identity the presence and quantity of glucose in the human body. By extension, there may be other molecular structures which this same technology can identity in the human body which, over time, the Company will focus upon. They may include the monitoring of drug usage or the presence of illicit drugs. They may also involve identifying hormones and various markers of disease.
The cornerstone of a company with a foundational platform technology is its intellectual property. We have pursued an active intellectual property strategy and have been granted 12 patents. We currently have 20 patents pending. We possess all right, title and interest to the issued patents.
About Our Team
Phil Bosua
Chief Executive Officer
Phil Bosua is an internationally recognized inventor and innovator. His expertise in lighting lead him to found LIFX (www.lifx.com) where he created the world’s first commercial smart light bulb. The 2012 crowdsourcing launch of his smart light bulb raised $1.3 million in six days and attracted $12 million in funding from Sequoia Capital (www.sequoiacap.com). This groundbreaking invention earned him the prestigious Edison Gold Award (www.edisonawards.com) presented by Elon Musk to innovators who create products that have a positive impact on the world. Bosua also founded RAAI, Inc., where he continued his innovative creation of new uses of light. Bosua said, “The time I have spent in the Visualant lab working on advancing their technology has been some of the most scintillating moments of my career. Ron Erickson and Visualant have provided support to allow me and the lab team to explore new products and discover new technologies. I’m excited by the technology platform we are creating, knowing that it will benefit millions of people around the world and be equally as good for our shareholders.”
LinkedIn: http://bit.ly/2yeBNR9
Press Release: http://bit.ly/2HJRZsJ
Ronald P. Erickson
CFO, President and Chairman of the Board.
Mr. Erickson has been a director and officer of the Company since April 24, 2003. He currently serves as the Company's Chairman, Chief Executive Officer and President. He was appointed to the positions of CEO and President on November 10, 2009. Earlier, he was appointed President and Chief Executive Officer of the Company on September 29, 2003, and resigned from this position on August 31, 2004 at which time he was appointed Chairman of the Board. A seasoned executive with more than 30 years of experience in the high technology, telecommunications, micro-computer, and digital media industries, Mr. Erickson was the founder of Know Labs. In addition to his Know Labs responsibilities he also serves as Chairman of ivi, Inc. a streaming media company and eCharge Corporation an Internet based transaction processing company. He is formerly Chairman, CEO and Co-Founder of Blue Frog Media, a mobile media and entertainment company; Chairman, CEO and Co-founder of GlobalTel Resources, a provider of telecommunications services; Chairman, Interim President and CEO of Egghead Software, Inc. the large software reseller where he was an original investor; Chairman and CEO of NBI, Inc.; and Co-founder of MicroRim, Inc. the database software developer. Earlier, Mr. Erickson practiced law in Seattle and worked in public policy in Washington, DC and New York, NY. Additionally, Mr. Erickson has been an angel investor and board member of a number of public and private technology companies. Mr. Erickson has a BA from Central Washington University, a MA from the University of Wyoming and a JD from the University of California, Davis. He is licensed to practice law in the State of Washington and the District of Columbia.
LinkedIn: http://bit.ly/2t2oE7T
Bill Owens
Know Labs Board of Directors
Admiral Owens is currently the co-founder and executive chairman of Red Bison Advisory Group, a company which identifies opportunities with proven enterprises in China, the Middle East, and the United States and creates dynamic partnerships focusing on: natural resources (oil, gas and fertilizer plants), real estate, and information and communication technology. Most recently, he was the chairman of the board of CenturyLink Telecom, the third largest telecommunications company in the United States and was on the advisory board of SAP USA. Owens serves on the board of directors at Wipro Technologies and is a director of the following private companies: Humm Kombucha, a beverage company and Versium. Owens is on the advisory board of the following private companies: Healthmine, Platform Science, Sarcos, Sierra Nevada Corporation, and Vodi. Owens is on the board of trustees at EastWest Institute, Seattle University, and an advisor to the Fiscal Responsibility Amendment (CFFRA) Association which aims to establish a balanced budget amendment to the US Constitution. He is also a member of the Council of Foreign Relations.
LinkedIn: http://bit.ly/2K6DJwx
Press Release: http://bit.ly/2JzG7PO
CONTACT US
Know Labs, Inc.
Jordyn Theisen, Ph. 206-903-1351
Email: jordyn@knowlabs.co
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/KNWN/company-info
Ticker: $KNWN
OTC Market Tier: OTCQB
CIK code: 0001074828
Company name: Know Labs, Inc.
Company website: http://bit.ly/knowlabs
Incorporated In: NV, USA
##### recent news/filings
Latest filings: http://www.otcmarkets.com/stock/KNWN/filings
Latest financials: http://www.otcmarkets.com/stock/KNWN/financials
Latest news: http://www.otcmarkets.com/stock/KNWN/news - http://finance.yahoo.com/q/h?s=KNWN+Headlines
Corporation WIKI:
Corporate website internet archive: http://bit.ly/knowlabs
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |